Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1581MR)

This product GTTS-WQ1581MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1581MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13481MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ10416MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ1631MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ6909MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ5351MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ11608MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ13531MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ328MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1F5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW